Sitagliptin has been shown, in several clinical studies to improve metabolic control in type 2 diabetes, both as monotherapy or in combination with metformin, sulfonylurea, thiazolidinediones or insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.